Connect Biopharma Raises $20.2M via Private Placement to Extend Cash Runway

Connect Biopharma Holdings Limited (Nasdaq: CNTB) has announced a securities purchase agreement for a private placement financing totaling approximately $20.2 million. The clinical-stage biopharmaceutical company will sell 6,130,000 ordinary shares to institutional accredited investors at a price of $3.25 per share. This strategic capital raise is designed to support the company's ongoing clinical operations and the development of treatments for inflammatory diseases. Crucially, management expects the gross proceeds to extend the company's operational cash runway into the second half of 2027. This financial cushion provides significant stability as the firm advances its clinical pipeline toward key milestones. Investors generally view the move as a positive step toward securing long-term funding despite the typical dilutive effects of equity financing.